ESMO 2019 | CheckMate 459: updates on nivolumab monotherapy for HCC

Thomas Yau

Thomas Yau, MD, Queen Mary Hospital, Hong Kong, China, gives an update on the CheckMate 459 trial (NCT02576509) results. This Phase III trial studies the use of nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma. This interview was recorded at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video